Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study)
复制标题
DOI：
10.1016/j.amjcard.2012.05.031
复制
发表时间：
2012-10-01
影响因子：
2.8
通讯作者：
Soni, Paresh N.
中科院分区：
文献类型：
--
作者：
Ballantyne, Christie M.;Bays, Harold E.;Soni, Paresh N.
AMR101 是一种 omega-3 脂肪酸制剂，含有 >= 96% 纯的二十碳五烯酸乙酯。在这项 3 期、多中心、安慰剂对照、随机、双盲、为期 12 周的临床试验 (ANCHOR) 中，对 AMR101 的疗效和安全性进行了评估，受试者为接受他汀类药物治疗且甘油三酯 (TG) 水平残留较高（≥ 200 且 = 40 和
AMR101 is an omega-3 fatty acid agent containing >= 96% pure icosapent-ethyl, the ethyl ester of eicosapentaenoic acid. The efficacy and safety of AMR101 were evaluated in this phase 3, multicenter, placebo-controlled, randomized, double-blinded, 12-week clinical trial (ANCHOR) in high-risk statin-treated patients with residually high triglyceride (TG) levels (>= 200 and = 40 and